Trial intelligence / Profile preview

Dihydroartemisinin-piperaquine efficacy and safety for uncomplicated malaria in Indonesia

ACTRN12614000753651Phase 4Not yet recruiting

Sponsor
Ministry of Health
Start
Aug 2014
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, open-label, single-arm trial of dihydroartemisinin and piperaquine in Malaria and malaria, sponsored by Ministry of Health. Primary endpoints: Dihydroartemisinin-piperaquine treatment failure rate and Adverse event rate. Planned start Aug 2014; status: not yet recruiting.

02

Drugs

dihydroartemisininpiperaquine
03

Conditions

Malariamalaria

Beyond the preview

Go deeper on ACTRN12614000753651.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ACTRN12614000753651.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call